The clinical study for the mechanism of pioglitazone-induced edema in patients with type 2 diabetes using a salt monitoring system
Not Applicable
Completed
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000001948
- Lead Sponsor
- Graduate School of Medicine, Yokohama City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1) Congestive heart failure or having a history of congestive heart failure 2) Severe ketosis, diabetic coma, or type 1 diabetes 3) Having a severe hepatic or renal dysfunction 4) Having a severe infection or injury, or during perioperative period 5) Having an allergic history of pioglitazone 6) Be pregnant or at risk of becoming pregnant 7) Receiving any diuretic medication 8) Evaluated as being inadequate by the physician-in-charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Onset of edema
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pioglitazone-induced edema in type 2 diabetes patients using salt monitoring?
How does pioglitazone compare to other thiazolidinediones in managing fluid retention in type 2 diabetes?
Are there specific biomarkers that predict susceptibility to pioglitazone-related edema in T2DM populations?
What are the optimal strategies for monitoring and managing sodium levels during pioglitazone therapy in diabetic patients?
How do PPAR-gamma agonists like pioglitazone influence renal sodium handling in type 2 diabetes compared to GLP-1 receptor agonists?